The BCL11B Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the BCL11B gene, providing a loss-of-function model for functional interrogation of this key transcriptional repressor. The polyclonal format captures a broad spectrum of editing events, supporting reproducible studies across heterogeneous cell pools.
HEK293T cells originate from human embryonic kidney tissue and are transformed by sheared adenovirus 5 DNA, resulting in stable expression of the SV40 large T antigen. This cell line is female-derived and exhibits exceptionally high transfectability, making it a preferred host for transient and stable genetic engineering. Its epithelial phenotype and robust growth characteristics facilitate consistent experimental outputs in signaling, epigenetics, and functional genomics assays.
BCL11B is a C2H2 zinc finger transcription factor that functions as a transcriptional repressor critical for T-cell lineage commitment, thymocyte development, and neuronal differentiation. It is regulated by upstream factors TCF7, NOTCH1, RUNX1, and IL7R, and represses targets including CDKN1A, BCL2L1, SIRT1, IL2, and ZBTB16. BCL11B interacts with the NuRD complex components HDAC1, HDAC2, and MTA2, as well as SIRT1 and COUP-TFII, linking it to epigenetic modulation, apoptosis, and cell cycle regulation. These interactions connect BCL11B to T-cell receptor, Notch, p53, and Wnt signaling pathways.
In the HEK293T background, BCL11B disruption is anticipated to alter transcriptional programs governing cell proliferation and programmed cell death, driven by its interactions with NuRD and SIRT1 complexes. Although HEK293T cells lack T-cell and neuronal lineage features, their high transfectability and well-defined signaling networks allow detailed dissection of BCL11B??s core transcriptional and epigenetic functions. This knockout model serves as a versatile platform for studying histone modification dynamics, complex assembly, and apoptotic signaling under controlled experimental conditions.
These polyclonal BCL11B knockout cells support a range of research applications, including mechanistic studies of BCL11B in T-cell acute lymphoblastic leukemia and neurodevelopmental disorders, functional genomics screening, and drug target validation. Representative assays include Western blotting and RT-qPCR for target gene analysis, flow cytometry for Annexin V apoptosis detection, ChIP-qPCR for histone modification profiling, luciferase reporter assays, transcriptome analysis by RNA-seq, and co-immunoprecipitation to examine NuRD complex interactions. For additional information or to place an order, please contact Ascent Research.
